Literature DB >> 10807744

Human ApoA-IV overexpression in transgenic mice induces cAMP-stimulated cholesterol efflux from J774 macrophages to whole serum.

N Fournier1, V Atger, J L Paul, M Sturm, N Duverger, G H Rothblat, N Moatti.   

Abstract

The role of apolipoprotein A-IV (apoA-IV) in lipoprotein metabolism has not been established. The aim of the present study was to investigate the role of apoA-IV in reverse cholesterol transport by comparing cellular cholesterol efflux to serum or serum fractions from control mice and from mice transgenic for human apoA-IV (HuA-IVTg mice). When Fu5AH hepatoma cells were used, the cholesterol efflux to serum from either control or transgenic mice was similar. When control J774 macrophage cells were used, a comparison of efflux to serum or lipoprotein-deficient serum (LPDS) failed to demonstrate any differences between control and transgenic mice. In contrast, when the J774 cells were pretreated with cAMP, there was a stimulation of efflux to whole serum or LPDS from HuA-IVTg mice. cAMP treatment had no effect on efflux to serum or LPDS from control mice. Pretreatment of the cells with cAMP did not enhance the efflux response to high density lipoprotein isolated from HuA-IVTg mouse serum. Our results suggest that apoA-IV, unassociated with high density lipoprotein particles, is responsible for enhanced cholesterol efflux. This study illustrates the role of lipid-free apolipoproteins in mediating cellular cholesterol efflux with use of a biological fluid and is potentially of physiological relevance, especially in apolipoprotein-rich extravascular fluids.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807744     DOI: 10.1161/01.atv.20.5.1283

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  15 in total

1.  Identification of ApoA4 as a sphingosine 1-phosphate chaperone in ApoM- and albumin-deficient mice.

Authors:  Hideru Obinata; Andrew Kuo; Yukata Wada; Steven Swendeman; Catherine H Liu; Victoria A Blaho; Rieko Nagumo; Kenichi Satoh; Takashi Izumi; Timothy Hla
Journal:  J Lipid Res       Date:  2019-08-28       Impact factor: 5.922

2.  Loss of Transcription Factor CREBH Accelerates Diet-Induced Atherosclerosis in Ldlr-/- Mice.

Authors:  Jong-Gil Park; Xu Xu; Sungyun Cho; Ann-Hwee Lee
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-07-14       Impact factor: 8.311

3.  The apolipoprotein A-IV Gln360His polymorphism predicts progression of coronary artery calcification in patients with type 1 diabetes.

Authors:  A Kretowski; J E Hokanson; K McFann; G L Kinney; J K Snell-Bergeon; D M Maahs; R P Wadwa; R H Eckel; L G Ogden; S K Garg; J Li; S Cheng; H A Erlich; M Rewers
Journal:  Diabetologia       Date:  2006-06-13       Impact factor: 10.122

4.  Apolipoprotein A-IV improves glucose homeostasis by enhancing insulin secretion.

Authors:  Fei Wang; Alison B Kohan; Tammy L Kindel; Kathryn L Corbin; Craig S Nunemaker; Silvana Obici; Stephen C Woods; W Sean Davidson; Patrick Tso
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-22       Impact factor: 11.205

5.  Apolipoprotein A-IV inhibits experimental colitis.

Authors:  Thorsten Vowinkel; Mikiji Mori; Christian F Krieglstein; Janice Russell; Fumito Saijo; Sulaiman Bharwani; Richard H Turnage; W Sean Davidson; Patrick Tso; D Neil Granger; Theodore J Kalogeris
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

Review 6.  Apolipoprotein A-IV: a protein intimately involved in metabolism.

Authors:  Fei Wang; Alison B Kohan; Chun-Min Lo; Min Liu; Philip Howles; Patrick Tso
Journal:  J Lipid Res       Date:  2015-02-01       Impact factor: 5.922

7.  Increased ABCA1 activity protects against atherosclerosis.

Authors:  Roshni R Singaraja; Catherine Fievet; Graciela Castro; Erick R James; Nathalie Hennuyer; Susanne M Clee; Nagat Bissada; Jonathan C Choy; Jean-Charles Fruchart; Bruce M McManus; Bart Staels; Michael R Hayden
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

8.  Numerous transcriptional alterations in liver persist after short-term enzyme-replacement therapy in a murine model of mucopolysaccharidosis type VII.

Authors:  Josh C Woloszynek; Marie Roberts; Trey Coleman; Carole Vogler; William Sly; Clay F Semenkovich; Mark S Sands
Journal:  Biochem J       Date:  2004-04-15       Impact factor: 3.857

9.  Plasminogen promotes cholesterol efflux by the ABCA1 pathway.

Authors:  Nathalie Pamir; Patrick M Hutchins; Graziella E Ronsein; Hao Wei; Chongren Tang; Riku Das; Tomas Vaisar; Edward Plow; Volker Schuster; Marlys L Koschinsky; Catherine A Reardon; Richard Weinberg; David A Dichek; Santica Marcovina; Godfrey S Getz; Jay W Heinecke
Journal:  JCI Insight       Date:  2017-08-03

10.  Interaction of ApoA-IV with NR4A1 and NR1D1 Represses G6Pase and PEPCK Transcription: Nuclear Receptor-Mediated Downregulation of Hepatic Gluconeogenesis in Mice and a Human Hepatocyte Cell Line.

Authors:  Xiaoming Li; Min Xu; Fei Wang; Yong Ji; W Sean DavidsoN; Zongfang Li; Patrick Tso
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.